A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients
Ta publikacja to tak naprawd wycieczka po wszystkich najwaniejszych dla wosw tematach
Research/Fundamental Mol
In SURMOUNT-1, nausea affected 33% of participants on the 15 mg dose versus 9% on placebo [2]
In metabolic-related trials, Novo Nordisk leads the pack Speaking of Novo Nordisk, the company remains a leader in terms of GLP-1 clinical trials, with twice as many as the nearest competitor, Eli Lilly
For example, a patient with a history consistent with IgE-mediated reaction to the antimicrobial sulfonamide trimethoprim-sulfamethoxazole can receive celecoxib, chlorthiazide, furosemide or other nonantimicrobial sulfonamides, as indicated